Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Stock analysts at Sidoti increased their Q1 2026 earnings per share (EPS) estimates for shares of Phio Pharmaceuticals in a report issued on Monday, March 9th. Sidoti analyst A. Hantman now forecasts that the company will post earnings per share of ($0.23) for the quarter, up from their prior forecast of ($0.24). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti also issued estimates for Phio Pharmaceuticals’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.01) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.20) EPS and FY2027 earnings at ($0.75) EPS.

PHIO has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Phio Pharmaceuticals in a research note on Tuesday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Price Performance

PHIO opened at $1.25 on Thursday. The firm has a market cap of $14.53 million, a PE ratio of -0.86 and a beta of 0.90. The stock has a 50-day moving average price of $1.13 and a 200-day moving average price of $1.53. Phio Pharmaceuticals has a 1 year low of $0.81 and a 1 year high of $4.19.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its earnings results on Thursday, March 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.19.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Cetera Investment Advisers raised its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,500 shares of the company’s stock after acquiring an additional 9,000 shares during the quarter. Cetera Investment Advisers owned approximately 0.39% of Phio Pharmaceuticals worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 57.31% of the stock is owned by institutional investors and hedge funds.

Key Phio Pharmaceuticals News

Here are the key news stories impacting Phio Pharmaceuticals this week:

• Positive Sentiment: Sidoti raised multiple quarterly and full‑year EPS estimates for PHIO, trimming projected losses across 2026–2027 (examples: FY2026 revised from ($1.06) to ($1.01); FY2027 from ($0.79) to ($0.75)) and bumping several quarterly forecasts by $0.01. This indicates a slightly improved operational/prognostic view from that analyst, which can be seen as a modest positive catalyst. Sidoti estimate revisions
• Neutral Sentiment: Phio will present at the Life Sciences Investor Forum on March 12, 2026 (11 AM EDT) — an opportunity to update investors on programs and milestones; such presentations can move the stock if material clinical or partnership news is disclosed, but by themselves are typically neutral until new data or guidance is provided. Investor forum presentation
• Neutral Sentiment: B2i Digital highlighted the Life Sciences Virtual Investor Forum (where Phio is a featured participant) — additional visibility for the company but not an immediate fundamental driver unless new disclosures are made. B2i Digital highlight

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.